MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine

ConclusionThese observations raise the probability that DMTs with immunosuppressive effects, such as cladribine, may be considered as a treatment option for selected MS patients with high disease activity during the COVID-19 pandemic.

http://link.springer.com/10.1007/s10072-021-05409-6

Source: Neurological Sciences - June 24, 2021 Category: Neurology Source Type: research